Cite
HARVARD Citation
Perl, A. et al. (n.d.). Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study. Lancet oncology. 18 (8), pp. 1061-1075. [Online].